



Volume 4, Issue 11
December 2025

Pharmacy Benefits Management- Medical Advisory Panel- VISN Pharmacist Executives E_z - MINUTES

Drugs (and Supplies) Added to the VA National Formulary WITHOUT Prior Authorization

- Insulin Aspart-szjj inj (MERILOG) biosimilar

Drugs (and Supplies) Added to the VA National Formulary WITH Prior Authorization

- Atezolizumab /hyaluronidase-tqjs inj (TECENTRIQ HYBREZA)
- Belimumab (BENLYSTA) inj lyph and inj soln
- Magnesium sulfate/potassium sulfate/sodium sulfate soln,oral (EQV-SUPREP)

Drugs (and Supplies) Kept on the VA National Formulary WITH Prior Authorization, MODIFIED RESTRICTIONS

- Obinutuzumab (GAZYVA) inj, sol

Drugs (and Supplies) Not Added to the VA National Formulary

- Brensocatib BRINSUPRI in non-cystic fibrosis bronchiectasis (NCFB)
- Delgocitinib (ANZUPGO) topical cream 2%.
- Humulin insulin products (NPH, Regular and 70/30)
- Tizanidine oral solution (ONTRALFY)

Formulary Drugs (and Supplies) with Prior Authorization Removed

- None

Drugs (and Supplies) Removed from the VA National Formulary

- Andexanet alfa (coagulation factor Xa [recombinant], inactivated -zhzo) (ANDEXXA)

New Guidance

- None

Updated documents – Criteria for Use

- None

Updated documents – Other

- HIV Preexposure Prophylaxis (PrEP) Clinical Recommendations
- Lasmiditan Provider Letter
- Menopausal Therapies in VA Table

Urgent/Emergent Formulary

- None

